Arvinas, Inc. (ARVN)
Nasdaq · Pharmaceutical Preparations · Manufacturing · CIK 1655759 · fiscal year ends in Dec
Closing price $7.91 on 29 Oct 2026; 52-week range $6.81 to $13.83.
Key figures
The last twelve months reported, with the latest price and balance sheet.
- Revenue, last twelve months
- $316.7M
- Revenue growth
- -15.0%
- Net income, last twelve months
- $9.3M
- Earnings per share
- $0.10
- Operating margin
- -5.7%
- Net margin
- 2.9%
- Free cash flow
- -$208.8M
- Return on equity
- 1.7%
- Market value
- $516.2M
- Price to earnings
- 79.0x
- Cash
- $94.3M
- Debt
- $500.0K
- Debt to equity
- 0.00
- Shares outstanding
- 65.3M
Financial statements
Revenue, profit and cash flow by fiscal year, each year linked to its annual report.
| Fiscal year | Year end | Revenue | Operating income | Net income | EPS | Free cash flow | Filing |
|---|---|---|---|---|---|---|---|
| FY2025 | 31 Dec 2025 | $262.6M | -$118.5M | -$80.8M | -$1.14 | -$275.7M | 10-K filed 24 Feb 2026 |
| FY2024 | 31 Dec 2024 | $263.4M | -$250.2M | -$198.9M | -$2.77 | -$261.1M | 10-K filed 11 Feb 2025 |
| FY2023 | 31 Dec 2023 | $78.5M | -$401.5M | -$367.3M | -$6.62 | -$350.7M | 10-K filed 27 Feb 2024 |
| FY2022 | 31 Dec 2022 | $131.4M | -$263.2M | -$282.5M | -$5.31 | -$280.3M | 10-K filed 23 Feb 2023 |
| FY2021 | 31 Dec 2021 | $53.6M | -$188.4M | -$191.0M | -$3.82 | $554.7M | 10-K filed 28 Feb 2022 |
By quarter
| Quarter | Quarter end | Revenue | Net income | EPS |
|---|---|---|---|---|
| Q2 FY2026 | 30 Jun 2026 | $249.7M | $169.4M | $2.58 |
| Q1 FY2026 | 31 Mar 2026 | $15.6M | -$57.6M | -$0.90 |
| Q4 FY2025 | 31 Dec 2025 | $9.5M | -$67.4M | -$1.10 |
| Q3 FY2025 | 30 Sep 2025 | $41.9M | -$35.1M | -$0.48 |
| Q2 FY2025 | 30 Jun 2025 | $22.4M | -$61.2M | -$0.84 |
| Q1 FY2025 | 31 Mar 2025 | $188.8M | $82.9M | $1.14 |
| Q4 FY2024 | 31 Dec 2024 | $59.2M | -$45.1M | -$0.63 |
| Q3 FY2024 | 30 Sep 2024 | $102.4M | -$49.2M | -$0.68 |
Company events
The newest 8-K filings of 114 held.
| Filed | Form | Event | Items |
|---|---|---|---|
| 4 Aug 2026 | 8-K | Results | 2.02, 9.01 |
| 25 Jun 2026 | 8-K | Shareholder vote | 5.07 |
| 22 Jun 2026 | 8-K | Leadership change | 5.02 |
| 16 Jun 2026 | 8-K | Other events | 8.01 |
| 2 Jun 2026 | 8-K | Investor update, Other events | 7.01, 8.01, 9.01 |
| 12 May 2026 | 8-K | Results | 2.02, 9.01 |
| 12 May 2026 | 8-K | Material agreement, Investor update | 1.01, 7.01, 9.01 |
| 1 May 2026 | 8-K | Investor update, Other events | 7.01, 8.01, 9.01 |
| 18 Mar 2026 | 8-K | Investor update, Other events | 7.01, 8.01, 9.01 |
| 24 Feb 2026 | 8-K | Results | 2.02, 9.01 |
| 12 Feb 2026 | 8-K | Leadership change | 5.02 |
| 8 Dec 2025 | 8-K | Investor update, Other events | 7.01, 8.01, 9.01 |
Every filing
The newest filings with the SEC of 216 held.
| Filed | Form | Period |
|---|---|---|
| 28 Sep 2026 | S-8 | – |
| 31 Aug 2026 | S-8 | – |
| 4 Aug 2026 | 10-Q | 30 Jun 2026 |
| 4 Aug 2026 | 8-K | 4 Aug 2026 |
| 25 Jun 2026 | 8-K | 24 Jun 2026 |
| 22 Jun 2026 | 8-K | 22 Jun 2026 |
| 16 Jun 2026 | 8-K | 11 Jun 2026 |
| 2 Jun 2026 | 8-K | 2 Jun 2026 |
| 12 May 2026 | 8-K | 12 May 2026 |
| 12 May 2026 | 8-K | 11 May 2026 |
| 11 May 2026 | 10-Q | 31 Mar 2026 |
| 1 May 2026 | 8-K | 1 May 2026 |
Insider trades
Form 4 trades by officers, directors and 10% owners, last 12 months.
| Traded | Insider | Type | Shares | Price | Value | Held after | Form 4 |
|---|---|---|---|---|---|---|---|
| 24 Jun 2026 | Saik Andrew, Chief Financial Officer | Sale under a trading plan | 5,696 | $8.16 | $46.5K | 187,432 | 24 Jun 2026 |
| 17 Jun 2026 | Cacace Angela M, Chief Scientific Officer | Sale under a trading plan | 2,576 | $7.59 | $19.6K | 180,390 | 18 Jun 2026 |
| 21 May 2026 | Teel Randy, President and CEO | Sale outside a trading plan | 2,209 | $9.04 | $20.0K | 285,009 | 22 May 2026 |
| 11 May 2026 | Saik Andrew, Chief Financial Officer | Sale outside a trading plan | 11,139 | $9.94 | $110.7K | 193,128 | 13 May 2026 |
| 11 May 2026 | Loomis David K, VP, Chief Accounting Officer | Sale outside a trading plan | 1,919 | $9.94 | $19.1K | 40,193 | 13 May 2026 |
| 11 May 2026 | Cacace Angela M, Chief Scientific Officer | Sale outside a trading plan | 9,657 | $9.94 | $96.0K | 182,966 | 13 May 2026 |
| 11 May 2026 | Berkowitz Noah, Chief Medical Officer | Sale outside a trading plan | 11,108 | $9.94 | $110.4K | 191,395 | 13 May 2026 |
| 11 May 2026 | Teel Randy, President and CEO | Sale outside a trading plan | 9,657 | $9.94 | $96.0K | 287,218 | 13 May 2026 |
| 18 Mar 2026 | Berkowitz Noah, Chief Medical Officer | Sale outside a trading plan | 6,435 | $11.10 | $71.4K | 202,503 | 19 Mar 2026 |
| 6 Mar 2026 | Morrison Briggs, Director | Purchase | 20,000 | $13.40 | $268.1K | 96,021 | 9 Mar 2026 |
| 27 Feb 2026 | Houston John G, Director | Sale outside a trading plan | 4,688 | $13.24 | $62.1K | 1,152,792 | 2 Mar 2026 |
| 27 Feb 2026 | Houston John G, Director | Sale outside a trading plan | 18,822 | $13.24 | $249.2K | 1,133,970 | 2 Mar 2026 |
Planned insider sales
Form 144 notices, filed when the sell order goes to the broker.
| Filed | Seller | Shares | Value | Planned sale |
|---|---|---|---|---|
| 22 Sep 2026 | SUNIL AGARWAL, Director | 23,105 | $196.2K | 22 Sep 2026 |
| 9 Sep 2026 | NOAH C BERKOWITZ, Former Officer | 37,200 | $328.9K | 9 Sep 2026 |
| 4 Sep 2026 | NOAH C BERKOWITZ, Former Officer | 8,300 | $78.4K | 4 Sep 2026 |
| 4 Aug 2026 | NOAH C BERKOWITZ, Officer | 30,000 | $264.0K | 4 Aug 2026 |
| 9 Jul 2026 | NOAH C BERKOWITZ, Former Affiliate | 24,000 | $201.5K | 9 Jul 2026 |
| 23 Jun 2026 | Andrew Saik, Officer | 5,846 | $47.6K | 24 Jun 2026 |
| 17 Jun 2026 | Angela Cacace, Officer | 2,642 | $19.6K | 17 Jun 2026 |
| 20 May 2026 | Randy Teel, Officer, Director | 2,197 | $20.0K | 21 May 2026 |
| 8 May 2026 | Angela Cacace, Officer | 9,834 | $99.4K | 11 May 2026 |
| 8 May 2026 | Randy Teel, Officer, Director | 9,834 | $99.4K | 11 May 2026 |
Large holders
Schedule 13D and 13G filings by holders of more than 5% of the voting shares.
| Filed | Holder | Schedule | Stake | Shares |
|---|---|---|---|---|
| 14 Aug 2026 | D. E. Shaw & Co., L.P. | 13G amended | 5.4% | 3.5M |
| 28 Apr 2026 | Vanguard Portfolio Management | 13G | 6.12% | 3.9M |
| 26 Mar 2026 | The Vanguard Group | 13G amended | 0% | 0 |
| 14 Nov 2025 | D. E. Shaw & Co., L.P. | 13G | 5.3% | 3.4M |
| 14 Nov 2025 | Citadel Advisors LLC | 13G amended | 0.4% | 264.2K |
Short interest
Shares sold short and not yet bought back, on each FINRA settlement date.
| Settlement | Shares short | Change | Days to cover |
|---|---|---|---|
| 15 Oct 2026 | 5.6M | +3.77% | 8.17 |
| 30 Sep 2026 | 5.4M | +8.08% | 6.58 |
| 15 Sep 2026 | 5.0M | +5.83% | 5.59 |
| 31 Aug 2026 | 4.7M | +16.28% | 8.04 |
| 14 Aug 2026 | 4.1M | +1.41% | 3.33 |
| 31 Jul 2026 | 4.0M | +0.39% | 6.96 |
| 15 Jul 2026 | 4.0M | -6.75% | 6.62 |
| 30 Jun 2026 | 4.3M | -5.01% | 4.59 |
Funds that hold it
From each fund's latest Form 13F.
240 funds held it at 30 Jun 2026: 106 added and 52 trimmed in the quarter. The largest:
| Fund | Shares | Value | Change in the quarter |
|---|---|---|---|
| BlackRock, Inc. | 7,609,123 | $63.2M | +811,539 |
| Vanguard Portfolio Management LLC | 4,123,399 | $34.3M | +233,771 |
| D. E. Shaw & Co., Inc. | 3,495,153 | $29.0M | -143,414 |
| Pfizer Inc | 3,457,815 | $27.7M | 0 |
| Armistice Capital, LLC | 2,796,000 | $23.2M | +818,000 |
| Vanguard Capital Management LLC | 2,714,163 | $22.6M | +24,801 |
| Two Sigma Investments, LP | 2,573,447 | $21.4M | +741,333 |
| State Street Corp. | 2,196,872 | $18.3M | +368,400 |
| Nextech Invest Ltd. | 1,122,713 | $17.1M | +583,319 |
| Geode Capital Management, LLC | 1,667,265 | $13.9M | +110,158 |
Peers
Companies in the same industry.
- Eli Lilly & Co. (LLY): revenue $86.5B, market value $1.29T
- Johnson & Johnson (JNJ): revenue $99.3B, market value $662.4B
- AbbVie Inc. (ABBV): revenue $64.4B, market value $513.9B
- Merck & Co., Inc. (MRK): revenue $66.6B, market value $361.0B
- Novartis AG (NVS): revenue $54.5B, market value $307.3B
- AstraZeneca PLC (AZN): revenue $58.7B, market value $270.6B
- Abbott Laboratories (ABT): revenue $46.6B, market value $180.9B
- Novo Nordisk A/S (NVO): revenue $46.8B, market value $174.8B
- Pfizer Inc. (PFE): revenue $63.7B, market value $170.7B
- Vertex Pharmaceuticals Inc. (VRTX): revenue $12.6B, market value $136.8B